Menu
PIVI works to promote investment in influenza vaccination readiness through research and partnering with global health experts. Our activities include collecting economic information related to influenza vaccination – including the cost-effectiveness and full impact of influenza vaccines in low- and middle-income countries – facilitating communication about the burden and severity of influenza, and establishing an evidence base for national investments in influenza vaccination programs
The Influenza Learning Agenda (ILA) is a multi-project initiative exploring the role of national influenza vaccination programs in pandemic readiness and vaccine distribution efficiency, with results expected in late 2023.
Cost-effectiveness models help justify investments in influenza vaccination programs by comparing their health benefits to alternative interventions, aiding decision-makers in resource allocation.
The Full Value Proposition, supported by the WHO, evaluates the broad benefits of vaccines, including next-gen influenza vaccines, through disease prevention, supply-demand analysis, and cost-benefit models, with a target completion in late 2024.
IPIES, a collaborative effort by the WHO, CDC, and The Task Force, evaluates and improves influenza vaccine campaigns in various countries, emphasizing programmatic efficiency for enhanced vaccine delivery.
Investing in KAP studies is essential for optimizing vaccine delivery, especially to high-risk and vulnerable populations, by understanding local contexts, beliefs, and hesitancies to tailor effective communication and outreach strategies.